Skip to main content

InvestorNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Presenting Key Findings from Three New Studies at ADA Scientific Sessions

DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, announced that company officials are presenting three new studies at the American Diabetes Association’s (“ADA”) 82nd Scientific Sessions; the sessions begin today and run through June 7, 2022, in New Orleans. According to the announcement, two of the studies demonstrated noticeable improvement in glucose control and reductions in blood pressure for users managing diabetes and hypertension and improvement in clinical measures for users with diabetes, stress and depression while the third study explored the impact the Dario solution has across the ethnicities of users living with Type 2 diabetes. Among the results of the studies are indications that Dario’s integrated approach to managing chronic conditions in one solution offers significant benefits for users with co-occurring conditions, that Dario’s holistic support focused on behavior change can positively impact outcomes for users living with diabetes and depression and/or stress, and that Dario’s solution has the ability to improve self-care across diverse populations. “We are thrilled to present several new studies showcasing Dario’s ability to positively impact health and outcomes across a wide range of factors,” said Dario scientific and clinical director and supervisor of studies Yifat Hershcovitz, PhD. In the press release. “Our deepening knowledge about the importance of an integrated solution approach has enormous potential to change the way people manage chronic conditions, and we are proud to share further insights with the scientific community this week.”

To view the full press release, visit

About DarioHealth Corp.

DarioHealth is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Making the right thing to do the easy thing to do. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.